Guidelines for treatment of autoimmune neuromuscular transmission disorders (Q33558942)

28 July 2017

title

Guidelines for treatment of autoimmune neuromuscular transmission disorders (English)

1 reference

28 July 2017

N E Gilhus

1 reference

European Federation of Neurological Societies

28 July 2017

object named as

European Federation of Neurological Societies

1 reference

28 July 2017

G O Skeie

1 reference

ORCID Public Data File 2021

28 July 2017

1 reference

author name string

S Apostolski

1 reference

28 July 2017

A Evoli

1 reference

28 July 2017

I Illa

1 reference

28 July 2017

L Harms

1 reference

28 July 2017

D Hilton-Jones

1 reference

28 July 2017

A Melms

1 reference

28 July 2017

J Verschuuren

1 reference

28 July 2017

H W Horge

1 reference

28 July 2017

publication date

12 April 2010

1 reference

European Journal of Neurology

28 July 2017

published in

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

893-902

1 reference

Unravelling the pathogenesis of myasthenia gravis

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Clinical use of immunosuppressive drugs: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Successful treatment of myasthenia gravis with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Ephedrine: effects on neuromuscular transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Terbutaline in myasthenia gravis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Prevention of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Mechanisms of action of cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Immunointervention with cyclosporin A in autoimmune neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Mycophenolate mofetil for myasthenia gravis: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Mycophenolate mofetil in the therapy of severe myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Clinical study of fk506 in patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Low-dose tacrolimus for intractable myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Successful treatment of refractory generalized myasthenia gravis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Rituximab for myasthenia gravis: three case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Myasthenia gravis: consequences for pregnancy, delivery, and the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Myasthenia gravis: management issues during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Course and treatment of myasthenia gravis during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

An improved diagnostic assay for Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Management of paraneoplastic neurological syndromes: report of an EFNS Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Phenotypic variants of autoimmune peripheral nerve hyperexcitability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Successful immunoglobulin treatment in a patient with neuromyotonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03019.X

10.1111/J.1468-1331.2010.03019.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference